An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function
LE 6101
Phase 1 other active
Quick answer
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function for Activated Phosphoinositide 3-Kinase Delta Syndrome is a Phase 1 program (other) at Pharming Technologies B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharming Technologies B.V.
- Indication
- Activated Phosphoinositide 3-Kinase Delta Syndrome
- Phase
- Phase 1
- Modality
- other
- Status
- active